Yago González‐Lama
A5027812355- Inflammatory Bowel Disease
- Microscopic Colitis
- Acute Lymphoblastic Leukemia research
- Eosinophilic Esophagitis
- Autoimmune and Inflammatory Disorders
- Liver Diseases and Immunity
- Pregnancy and Medication Impact
- Helicobacter pylori-related gastroenterology studies
- Childhood Cancer Survivors' Quality of Life
- Diverticular Disease and Complications
- Diagnosis and treatment of tuberculosis
- Immunodeficiency and Autoimmune Disorders
- Chronic Lymphocytic Leukemia Research
- Gastrointestinal disorders and treatments
- Spondyloarthritis Studies and Treatments
- Pancreatitis Pathology and Treatment
- COVID-19 and healthcare impacts
- Iron Metabolism and Disorders
- Mycobacterium research and diagnosis
- Biosimilars and Bioanalytical Methods
- Tuberculosis Research and Epidemiology
- COVID-19 Clinical Research Studies
- Health Systems, Economic Evaluations, Quality of Life
- Pediatric Hepatobiliary Diseases and Treatments
- Hidradenitis Suppurativa and Treatments
Hospital Universitario 12 De Octubre
2024-2025
Hospital Universitario Puerta de Hierro Majadahonda
2015-2024
RELX Group (Netherlands)
2019
Hospital Universitario de La Princesa
2005-2012
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
2008-2011
Hospital Universitario de Getafe
2009
Universidad Autónoma de Madrid
2007
Hospital Universitario La Paz
2005
Hospital La Luz
2005
The purpose of the study was to determine role fecal calprotectin and lactoferrin in prediction inflammatory bowel disease relapses, both patients with ulcerative colitis (UC) Crohn's (CD), a large, long-term, follow-up study. prospective multicenter included CD UC who had been clinical remission for 6 months. At baseline, provided single stool sample determination. Follow-up 12 months showing no relapse until activity flare relapsing patients. In all, 163 (89 CD, 74 UC) were included....
This article reports on the sixth scientific workshop of European Crohn's and Colitis Organisation [ECCO] pathogenesis extraintestinal manifestations [EIMs] in inflammatory bowel disease [IBD]. paper has been drafted by 15 ECCO members 6 external experts [in rheumatology, dermatology, ophthalmology, immunology] from 10 countries USA. Within workshop, contributors formed subgroups to address specific areas. Following a comprehensive literature search, supporting text was finalized under...
The aim was to evaluate the efficacy and tolerance of oral intravenous iron treatment in anemic inflammatory bowel disease (IBD) patients, considering both hematological quality-of-life outcomes.We performed a prospective multicenter study IBD patients with deficiency anemia. Patients having hemoglobin >10 g/dL were prescribed ferrous sulfate. If <10 g/dL, (sucrose) administered. Oral iron-intolerant changed treatment. Clinical (Truelove/Harvey-Bradshaw), (response defined as normalization),...
The aims of this study were to assess the risk relapse after discontinuation anti-tumor necrosis factor (anti-TNF) drugs in patients with inflammatory bowel disease (IBD), identify factors associated relapse, and evaluate overcome retreatment same anti-TNF those who relapsed.This was a retrospective, observational, multicenter study. IBD had been treated anti-TNFs whom these discontinued clinical remission achieved included.A total 1,055 included. incidence rate 19% 17% per patient-year...
Abstract Background Large real-world-evidence studies are required to confirm the durability of response, effectiveness, and safety ustekinumab in Crohn’s disease (CD) patients real-world clinical practice. Methods A retrospective, multicentre study was conducted Spain with active CD who had received ≥1 intravenous dose for ≥6 months. Primary outcome retention rate; secondary outcomes were identify predictive factors drug retention, short-term remission (week 16), loss response efficacy...
The aim of the study was to evaluate incidence abnormality liver tests (LTs) or hepatotoxicity in a large group inflammatory bowel disease (IBD) patients and, specifically, assess azathioprine (AZA)/mercaptopurine (MP)-induced injury long-term follow-up study.All consecutive IBD followed for at least 5 years were included this retrospective study. LTs including alanine transaminase, aspartate alkaline phosphatase, gamma-glutamyl transferase, and bilirubin periodically monitored....
Aim: Anti-tumor necrosis factor (TNF)-alpha agents are widely used for the treatment of both inflammatory bowel disease (IBD) and psoriasis. Psoriatic skin lesions induced by anti-TNF have been described in patients with IBD. We report a case series psoriasis IBD patients.
Aliment Pharmacol Ther 2011; 34: 544–554 Summary Background Low thiopurine-methyl-transferase (TPMT) activity and high 6-thioguanine-nucleotide (6TGN) concentrations have been linked to therapeutic success in inflammatory bowel disease patients treated with thiopurines; however, this has not implemented clinical practice. Aim To identify a threshold value for TPMT or 6TGN concentrations, their capability predict treatment safety efficacy. Methods Prospective multicentre study including...
An expanding number of monogenic defects have been identified as causative severe forms very early-onset inflammatory bowel diseases [VEO-IBD]. The present study aimed at defining how next-generation sequencing [NGS] methods can be used to improve identification known molecular diagnosis and adapt treatment.A total 207 children were recruited in 45 paediatric centres through an international collaborative network [ESPGHAN GENIUS working group] with a clinical presentation VEO-IBD [n = 185]...
To evaluate efficacy and safety of oral tacrolimus in cases fistulizing Crohn's disease (FCD), which is refractory to conventional therapy including infliximab. Patients with fistulas, previously unsuccessfully treated all (i.e., antibiotics, azathioprine, or 6-mercaptopurine infliximab), were enrolled a prospective, uncontrolled, open-label study long-term treatment (0.05 mg/kg every12 h). The evaluation the clinical response was complemented by use perianal activity index (PCDAI) magnetic...
Cyclosporin (CsA) and infliximab (IFX) have proven efficacy in avoiding colectomy patients with steroid-refractory ulcerative colitis (UC).To assess the clinical outcome of treated IFX after CsA failure for acute flares UC.Medical records a UC flare who did not respond to or relapsed soon hospital discharge, followed rescue therapy IFX, were reviewed retrospectively.Sixteen included, 69% extensive UC. Thirteen had moderate-to-severe disease activity at time was started. Median between...
Abstract Background Anti-TNF availability has been associated with a decrease of first intestinal resections in patients Crohn’s Disease (CD). However, few studies have evaluated the impact biological therapies medical management postoperative CD and its long-term outcomes. We aimed to assess time trends strategies for setting after resection rate second surgeries (surgical recurrence –sPOR-) through last three decades. Methods Adult who underwent ileocolic anastomosis between 1990 2020 at...
Abstract Background Postoperative recurrence (POR) in patients with Crohn’s disease (CD) can be prevented early postoperative use of thiopurines or anti-TNFs. However, the benefit medical prophylaxis has not been assessed long-term. We aimed to assess risk a second intestinal resection (surgical POR -sPOR-) for CD according prevention after first resection. Methods Adult who underwent ileocolic anastomosis between 2000 and 2020 had at least one year clinical follow-up, were identified from...